Adrenocorticotropic Hormone
Metastatic Prostate Carcinoma
Explore 229 assets in Metastatic Prostate Carcinoma →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Astellas Pharma Global Development, Inc.
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07005154CT.gov A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adrenocorticotropic Hormone (this asset) | Astellas Pharma Global Development, Inc. | P2 | CCC · 48 |
| AXUMIN | VA Greater Los Angeles Healthcare System | P4 | BBB |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Prednisone | Mayo Clinic | P4 | BB |
| Abiraterone | Mayo Clinic | P4 | BB |
| Pembrolizumab | CuraCell TX AB | P2 | BB |
| Cabazitaxel | AstraZeneca | P4 | BB |
| Degarelix | Praful Ravi, MB BCHir, MRCP | P3 | BB |
| Sipuleucel-T | Yale University | P2 | BB |
+42 more in the Metastatic Prostate Carcinoma cohort
Other indications for Adrenocorticotropic Hormone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Multiple Sclerosis | — | P4 | B · 61 |
| Prostate Cancer | — | P2 | CC · 46 |
| Infantile Spasms | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adrenocorticotropic Hormone in Metastatic Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adrenocorticotropic-hormone-metastatic-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →